When the Phase 2 retatrutide data landed in the New England Journal of Medicine in 2023, the obesity medicine field took notice. A triple agonist — targeting GLP-1, GIP, and glucagon receptors simultaneously — was producing weight loss figures that surpassed anything seen in a randomized controlled trial at the time. Fast forward to December 2025, and the Phase 3 TRIUMPH-4 trial results pushed those numbers even higher, cementing retatrutide's position as the most potent pharmacologic weight loss agent ever tested in a Phase 3 setting. Here is a structured look at how the data evolved from Phase 2 to Phase 3, what changed between the two trials, and what the tolerability signals mean for anyone following this drug's path toward regulatory review.
The Phase 2 trial (published in NEJM 2023; Jastreboff et al.; NCT04881760) enrolled 338 adults with obesity or overweight with at least one weight-related comorbidity, excluding individuals with type 2 diabetes. Participants received once-weekly subcutaneous injections across doses of 1mg, 4mg, 8mg, or 12mg, or placebo, over 48 weeks of treatment.
At the 12mg dose — the highest tested — mean weight loss reached 24.2% at 48 weeks, compared to approximately 2.1% in the placebo group. The responder data was equally striking:
To put that in perspective: tirzepatide's SURMOUNT-1 trial, the prior benchmark for pharmacologic weight loss, reported a mean of 20.9% at its 15mg dose. Retatrutide's Phase 2 results — from a smaller, shorter trial — already exceeded that figure. The cardiometabolic data was also notable. At 24 weeks, the 12mg group showed a 34.0% reduction in fasting triglycerides and a 17.3% reduction in total cholesterol, alongside improvements in LDL across the higher dose arms.
TRIUMPH-4, Eli Lilly's Phase 3 trial, extended treatment to 68 weeks and reported a mean weight loss of 28.7% at the 12mg dose — described in the December 2025 press release as the highest ever recorded in a Phase 3 obesity trial. That represents an approximately 4.5 percentage point gain over the Phase 2 result at the same dose, in a longer, larger, more rigorous trial design.
The comparison below summarizes the key efficacy data across both stages:
| Parameter | Phase 2 (12mg, 48 weeks) | TRIUMPH-4 Phase 3 (12mg, 68 weeks) |
|---|---|---|
| Mean weight loss | ~24.2% | 28.7% |
| ≥20% weight loss | 64% | Not yet reported in peer review |
| ≥25% weight loss | 48% | Not yet reported in peer review |
| Treatment duration | 48 weeks | 68 weeks |
| Trial phase | Phase 2 | Phase 3 |
| Placebo comparison | ~2.1% weight loss | Pending peer-reviewed publication |
It is worth noting that the peer-reviewed Phase 3 publication remains pending as of April 2026, meaning full responder analyses, placebo-subtracted figures, and subgroup data are not yet publicly available in a vetted format.
Several factors likely contributed to the improvement in mean weight loss between Phase 2 and TRIUMPH-4. The most straightforward explanation is duration. At 48 weeks in Phase 2, many participants in the higher dose groups had not yet reached their biological weight loss plateau. Adding 20 additional weeks of treatment — to 68 weeks total in TRIUMPH-4 — allows more participants to achieve maximal response, pulling the mean higher.
The titration schedule also evolved. In Phase 2, participants escalated to their target maintenance dose by approximately week 12, using either a 2mg or 4mg initial dose. TRIUMPH-4 used a more gradual five-step schedule: 2mg (weeks 1–4) → 4mg (weeks 5–8) → 6mg (weeks 9–12) → 9mg (weeks 13–16) → 12mg maintenance from week 17 onward. This slower escalation is consistent with what obesity medicine specialists know about GLP-1-based therapies generally: a more deliberate titration can improve tolerability early on, potentially allowing more participants to persist at the full maintenance dose and thereby contribute to a higher observed mean weight loss over time.
Phase 3 trials are also larger and more diverse, which affects population-level averages. Increased adherence support, standardized counseling protocols, and site-level training consistency can all influence outcomes in ways that are difficult to disentangle from the pharmacology itself. What the data shows unambiguously, however, is that retatrutide's triple agonist mechanism — sometimes called "triple G" in patient communities — produces durable, progressive weight loss that continues well past the 24-week primary endpoint window.
The tolerability data from TRIUMPH-4 deserves careful attention. Discontinuation rates at the 12mg dose reached 18.2%, compared to 4.0% in the placebo arm — and notably, some discontinuations were attributed to perceived excessive weight loss, an unusual finding that reflects the potency of the drug. The 9mg arm showed a discontinuation rate of 12.2%.
Dysesthesia — abnormal skin sensations including tingling, burning, or hypersensitivity — emerged as a more prominent signal in Phase 3 than in Phase 2. In TRIUMPH-4, dysesthesia was reported in 20.9% of participants at 12mg and 8.8% at 9mg, compared to 0.7% in the placebo group. In Phase 2, the comparable figure (hyperesthesia/dysesthesia by MedDRA terminology) was 12.9% at 12mg versus 1.4% placebo — and 14.3% in the 8mg arm using a 4mg initial dose.
The increase from approximately 12.9% in Phase 2 to 20.9% in Phase 3 likely reflects longer drug exposure, a larger and more diverse sample, and potentially greater sensitivity in adverse event capture within a more rigorous Phase 3 reporting infrastructure. Gastrointestinal events — nausea, diarrhea, vomiting — remained the most common adverse effects across both trials, consistent with the GLP-1 component of the mechanism. These were dose-dependent and most pronounced during the titration period.
As of April 2026, Eli Lilly has not yet filed a New Drug Application (NDA) for retatrutide with the FDA, and no approval timeline has been publicly confirmed. The peer-reviewed Phase 3 publication from TRIUMPH-4 is also still pending, meaning the full dataset — including confidence intervals, subgroup analyses, and safety tables — has not yet undergone formal peer review.
What the available data does establish is a compelling efficacy trajectory. From a 24.2% mean weight loss in Phase 2 to a 28.7% Phase 3 result, retatrutide commonly referred to as reta in patient communities, has now demonstrated greater average weight loss than any pharmacologic agent previously tested in a large randomized trial. The mechanism — simultaneously reducing food noise through GLP-1 signaling, improving metabolic efficiency through GIP, and increasing energy expenditure through glucagon receptor activation — appears to drive weight loss well beyond what single or dual agonists achieve.
The path from TRIUMPH-4 results to an NDA filing, and from filing to a potential FDA decision, typically spans months to years. Regulatory review will assess the full benefit-risk profile, including the dysesthesia signal and discontinuation rates at the highest dose. How Lilly structures its label application — dose range, indicated population, safety language — will shape how this drug ultimately enters clinical practice, if approved.
For anyone tracking retatrutide's development closely, joining the waitlist at glp3md.com is a way to stay informed as Phase 3 publications emerge and the regulatory timeline becomes clearer. glp3md maintains a waitlist for individuals interested in retatrutide and provides ongoing updates as new clinical data becomes available. Joining the waitlist does not guarantee access to medication, treatment, or a prescription — retatrutide is not FDA-approved, and no promises are made about future availability. It is simply a way to ensure that when the landscape changes, informed individuals are positioned to act on accurate, clinically grounded information.
Join the waitlist for priority access to a prescribing physician when retatrutide receives FDA approval.
Join the WaitlistThis article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not FDA approved as of publication. Clinical data referenced is from publicly available trial publications. Consult a qualified healthcare provider before making any treatment decisions.